CompletedNCT02307682HAWKUpdated Jan 16, 2025Results posted

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

A Phase 3 interventional study of Brolucizumab ophthalmic solution and Aflibercept ophthalmic solution in Neovascular Age-Related Macular Degeneration and Choroidal Neovascularization, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Alcon Research · Phase 3, Interventional, and Treatment

Phase: Phase 3
Study type: Interventional
Enrollment: 1,775
Allocation: Randomized
Ages: 50 Years and older
Sex: All

Study summary

The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Read the detailed description

Subjects were randomized to brolucizumab 3 mg, brolucizumab 6 mg,and aflibercept 2 mg in a 1:1:1 ratio. Subjects in all treatment arms received 3 monthly loading doses (Day 0, Week 4 and Week 8), followed by a maintenance regimen, until the end of the study (Week 96/Exit). All subjects attended pre-specified visits every 4 weeks.

Subjects in the brolucizumab 3 mg and brolucizumab 6 mg arms followed a q12w/q8w maintenance regimen. Within the q12w/q8w regimen, the initial treatment after the loading phase was q12w (1 injection every 12 weeks). If disease activity was identified by the masked investigator at any of the disease activity assessments, dosing was adjusted to q8w (1 injection every 8 weeks) ("q12w/q8w regimen"). Once subjects were adjusted to the q8w interval, they stayed on that interval until the end of the study.

Subjects in the aflibercept 2 mg arm followed a q8w maintenance regimen until the end of the study.

Results reported up to Week 48 are based on the database locked for the primary analysis at Week 48. Results reported after Week 48 are based on the database locked at the end of study (final analysis).

Conditions studied

Neovascular Age-Related Macular Degeneration
Choroidal Neovascularization

Browse trials for

Keywords

Who can participate

Ages eligible: 50 Years and older
Sexes eligible: All
Accepts healthy volunteers: No

Eligibility criteria

Key Inclusion Criteria:

Provide written informed consent
Active choroidal neovascularization (CNV) lesions secondary to age-related macular degeneration (AMD) that affected the central subfield in the study eye at Screening;
Total area of CNV comprising >50% of the total lesion area in the study eye at Screening;
Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening;
Best Corrected Visual Acuity (BCVA) between 78 and 23 letters, inclusive, in the study eye at Screening and Baseline using Early Treatment Diabetic Retinopathy Study (ETDRS) testing.

Key Exclusion Criteria:

Any active intraocular or periocular infection or active intraocular inflammation in either eye at Baseline;
Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion in the study eye at Screening;
Subretinal blood affecting the foveal center point and/or >50% of the lesion of the study eye at Screening;
Any approved or investigational treatment for neovascular age-related macular degeneration (nAMD) in the study eye at any time;
Retinal pigment epithelial rip/tear in the study eye at Screening or Baseline or current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to Baseline;
Pregnant or nursing women; women of child-bearing potential;
Stroke or myocardial infarction in the 90-day period prior to Baseline.

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Outcomes assessor)
Enrollment: 1,775 participants (actual)

Study arms

Experimental
Brolucizumab 3 mg
Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
Drug: Brolucizumab ophthalmic solution
Experimental
Brolucizumab 6 mg
Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
Drug: Brolucizumab ophthalmic solution
Active comparator
Aflibercept 2 mg
Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Drug: Aflibercept ophthalmic solution

Interventions

DrugBrolucizumab ophthalmic solution
Ophthalmic solution for IVT injection
Also known as: RTH258
DrugAflibercept ophthalmic solution
Ophthalmic solution for IVT injection
Also known as: EYLEA®

What researchers measure

Primary outcomes

Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Week 48

Secondary outcomes

Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. For each subject, this endpoint was defined as the average of the changes from baseline to Weeks 36, 40, 44, and 48. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 36, 40, 44, 48
Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48
Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w (one injection every 8 weeks) need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for brolucizumab 3mg and 6 mg arms only.
Time frame: Weeks 16, 20, 28, 32, 40, 44, 48
Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20)
Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.
Time frame: Weeks 16, 20, 28, 32, 40, 44, 48
Proportion of Subjects With Positive q12 Treatment Status up to Week 96
Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.
Time frame: Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96
Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20)
Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.
Time frame: Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 84, 88, 92, 96
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye
BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly (0-100 letters). A score of 65 to 70 letters represents a low to moderate visual acuity. Baseline was defined as the last measurement prior to first treatment. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Change From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye
CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Spectral-Domain Optical Coherence Tomography (SD-OCT), a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye
CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 36, 40, 44, 48
Average Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye
CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 84, 88, 92, 96
Average Change From Baseline in CSFTtot Over the Period Week 4 Through Week 48/96 - Study Eye
CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Change From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye
CNV lesion size (the area of new blood vessels in the choroid layer of the retina) size was measured using fluorescein angiography (FA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 12, 48, 96
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye
Central subfield neurosensory retinal thickness was assessed using SD-OCT. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye
Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye
Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye
Sub-RPE fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of sub-RPE fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid at Each Post-baseline Visit - Study Eye
Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Number of Subjects With Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) Present Between Week 36 to Week 48, Reported by Number of Visits
Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis. For each subject, the number of visits with SRF and/or IRF fluid is analyzed.
Time frame: Weeks 36, 40, 44, 48
Percentage of Subjects With Disease Activity Present (q8 Treatment Need = "Yes") at Week 16 - Study Eye
A disease activity assessment (DAA) was performed to identify q8 treatment need. 95% CI for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.
Time frame: Week 16
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96
The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) is a validated questionnaire that collects 25 vision-targeted responses from age-related macular degeneration (AMD) subjects. The 25 questions pertain to global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision (2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (1), and ocular pain (2). Each response is converted to a 0 to 100 sub-scale, with the lowest and highest possible scores set at 0 and 100 points, respectively. The overall composite score (0 to 100) is obtained by averaging the 25 sub-scale scores. A high score represents better functioning.
Time frame: Baseline, Weeks 24, 48, 72, 96
Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) Status at Week 48 (Brolucizumab Only)
Serum samples were collected and assessed for anti-drug antibody status. Subjects were categorized as ADA negative when one of the following was met: ADA negative at all time points (predose and postdose); ADA negative at predose and no titer values above 10 at all other time points; or ADA titer of 10 at predose but negative at all other time points. ADA induced was defined as ADA negative at predose with postdose titer value greater than or equal to a titer of 30 at any timepoint. ADA boosted was defined as ADA positive at predose with postdose titer values that increased by at least two dilutions (9-fold) from their respective predose value at any time point. Hypothesis testing not pre-specified.
Time frame: Week 48
Percentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye
Intraretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.
Time frame: Baseline, Weeks 12, 48, 96
Percentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye
Subretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.
Time frame: Baseline, Weeks 12, 48, 96

Results

Posted Oct 31, 2019

Participant flow

Subjects were recruited from investigative sites located in Argentina, Australia, Canada, Colombia, Israel, Japan, Mexico, New Zealand, Panama, Puerto Rico, and USA.

Participant flow — Overall Study
Milestone	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Started	360	361	361
Randomized and treated	358	360	360
Completed	310	304	297
Not completed	50	57	64
Withdrew: Adverse event	9	8	12
Withdrew: Lack of efficacy	1	0	1
Withdrew: Physician decision	2	2	8
Withdrew: Progressive disease	1	0	0
Withdrew: Withdrawal by subject	26	34	23
Withdrew: Death	9	7	12
Withdrew: Lost to follow-up	1	5	6
Withdrew: Protocol deviation	0	0	2
Withdrew: Other	1	1	0

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye

BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Time frame:: Baseline, Week 48
Reported as:: Mean · letters

Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye
letters	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye	5.9 ± 13.49	6.4 ± 14.40	7.0 ± 13.16

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · p = 0.0003 (1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.) · Least squares mean difference: -0.6 · 95% CI -2.5 to 1.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · p = <0.0001 (1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.) · Least squares mean difference: -0.2 · 95% CI -2.1 to 1.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryAverage Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. For each subject, this endpoint was defined as the average of the changes from baseline to Weeks 36, 40, 44, and 48. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Time frame:: Baseline, Weeks 36, 40, 44, 48
Reported as:: Mean · letters

Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye
letters	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye	6.0 ± 13.37	6.5 ± 13.85	6.9 ± 12.61

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · p = 0.0001 (1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.) · Least squares mean difference: -0.5 · 95% CI -2.4 to 1.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · p = <0.0001 (1-sided p-value reported. Hypothesis tested according to the pre-specified hierarchical testing that ensures the global type I error rate at 0.05.) · Least squares mean difference: 0.0 · 95% CI -1.9 to 1.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryProportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w (one injection every 8 weeks) need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for brolucizumab 3mg and 6 mg arms only.

Time frame:: Weeks 16, 20, 28, 32, 40, 44, 48
Reported as:: Number · proportion of subjects

Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48
proportion of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg
Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48	0.4939 (0.4393 to 0.5461)	0.5563 (0.5016 to 0.6075)

SecondaryProportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20)

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.

Time frame:: Weeks 16, 20, 28, 32, 40, 44, 48
Reported as:: Number · proportion of subjects

Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20)
proportion of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg
Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the First q12 Cycle (Week 16, Week 20)	0.8085 (0.7454 to 0.8574)	0.8539 (0.7987 to 0.8950)

SecondaryProportion of Subjects With Positive q12 Treatment Status up to Week 96

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.

Time frame:: Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96
Reported as:: Number · proportion of subjects

Proportion of Subjects With Positive q12 Treatment Status up to Week 96
proportion of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg
Proportion of Subjects With Positive q12 Treatment Status up to Week 96	0.3973 (0.3427 to 0.4514)	0.4537 (0.3984 to 0.5072)

SecondaryProportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20)

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A DAA was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% CIs were derived from the LOGLOG transformation. No hypothesis testing was performed. This outcome measure was pre-specified for the brolucizumab 3 mg and 6 mg arms only.

Time frame:: Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96
Reported as:: Number · proportion of subjects

Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20)
proportion of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg
Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12 Cycle (Week 16, Week 20)	0.6504 (0.5749 to 0.7159)	0.6963 (0.6270 to 0.7554)

SecondaryChange From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Mean · letters

Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
letters	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	3.7 ± 8.36	3.8 ± 9.77	4.2 ± 7.93
Change from baseline at Week 8	5.7 ± 8.83	5.5 ± 10.71	6.1 ± 9.48
Change from baseline at Week 12	5.7 ± 10.19	6.0 ± 11.71	6.3 ± 10.41
Change from baseline at Week 16	5.7 ± 11.44	6.3 ± 11.65	6.1 ± 10.89
Change from baseline at Week 20	6.2 ± 11.40	6.2 ± 12.30	7.1 ± 11.25
Change from baseline at Week 24	6.1 ± 11.95	6.4 ± 12.50	6.8 ± 11.72
Change from baseline at Week 28	6.2 ± 12.67	6.7 ± 13.23	6.7 ± 12.30
Change from baseline at Week 32	5.6 ± 13.42	6.8 ± 13.41	6.6 ± 12.43
Change from baseline at Week 36	5.6 ± 13.45	6.5 ± 13.74	7.1 ± 12.46
Change from baseline at Week 40	6.2 ± 13.96	6.6 ± 14.55	6.9 ± 12.96
Change from baseline at Week 44	6.2 ± 14.05	6.6 ± 14.01	6.7 ± 13.37
Change from baseline at Week 48	5.9 ± 13.49	6.4 ± 14.40	7.0 ± 13.16
Change from baseline at Week 52	6.2 ± 14.00	6.2 ± 14.58	6.8 ± 14.10
Change from baseline at Week 56	6.2 ± 14.08	6.1 ± 14.88	7.1 ± 13.31
Change from baseline at Week 60	6.2 ± 14.26	6.2 ± 14.72	6.7 ± 13.96
Change from baseline at Week 64	5.9 ± 14.67	6.0 ± 15.16	6.6 ± 13.75
Change from baseline at Week 68	6.0 ± 14.60	5.9 ± 15.10	6.5 ± 13.95
Change from baseline at Week 72	6.0 ± 14.95	5.6 ± 14.80	6.2 ± 14.50
Change from baseline at Week 76	6.2 ± 14.91	5.9 ± 15.09	6.3 ± 14.21
Change from baseline at Week 80	6.1 ± 14.83	6.1 ± 15.33	5.8 ± 14.42
Change from baseline at Week 84	5.8 ± 15.01	5.5 ± 14.94	5.6 ± 14.36
Change from baseline at Week 88	5.8 ± 15.43	5.7 ± 15.45	5.8 ± 14.67
Change from baseline at Week 92	5.8 ± 15.48	5.8 ± 15.21	5.9 ± 14.64
Change from baseline at Week 96	5.4 ± 15.86	5.6 ± 15.62	5.6 ± 14.78

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -1.4 to 0.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -1.4 to 1.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -1.4 to 1.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.3 · 95% CI -1.7 to 1.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.3 · 95% CI -1.8 to 1.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.0 · 95% CI -1.5 to 1.6Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -1.8 to 1.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.5 · 95% CI -1.1 to 2.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.6 · 95% CI -2.2 to 1.0Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.5 · 95% CI -2.2 to 1.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.4 · 95% CI -2.1 to 1.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -1.9 to 1.6Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -1.9 to 1.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.4 · 95% CI -1.4 to 2.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.5 · 95% CI -2.4 to 1.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.6 · 95% CI -1.2 to 2.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -1.0 · 95% CI -2.9 to 0.8Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -2.1 to 1.6Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.3 · 95% CI -2.2 to 1.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.1 · 95% CI -1.9 to 2.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -2.1 to 1.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.2 · 95% CI -1.8 to 2.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.6 · 95% CI -2.5 to 1.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -2.1 to 1.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -2.2 to 1.8Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -2.2 to 1.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.5 · 95% CI -2.5 to 1.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.6 · 95% CI -2.7 to 1.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -2.1 to 1.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -2.2 to 1.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.3 · 95% CI -2.3 to 1.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -2.2 to 1.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -2.1 to 2.0Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -2.2 to 1.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.2 · 95% CI -2.0 to 2.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.3 · 95% CI -2.4 to 1.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.3 · 95% CI -1.8 to 2.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.0 · 95% CI -2.1 to 2.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.6 · 95% CI -1.5 to 2.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.7 · 95% CI -1.4 to 2.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.6 · 95% CI -1.5 to 2.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.3 · 95% CI -1.8 to 2.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.4 · 95% CI -1.8 to 2.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.3 · 95% CI -1.9 to 2.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.3 · 95% CI -1.9 to 2.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.4 · 95% CI -1.8 to 2.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.3 · 95% CI -1.9 to 2.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.5 · 95% CI -1.6 to 2.7Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryAverage Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Mean · letters

Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye
letters	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline over the period Week 4 to 48	5.7 ± 10.43	6.2 ± 11.62	6.5 ± 10.49
Change from baseline over the period Week 4 to 96	5.8 ± 12.06	6.0 ± 12.73	6.4 ± 11.76

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.4 · 95% CI -1.9 to 1.1Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.0 · 95% CI -1.5 to 1.6Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -1.8 to 1.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.0 · 95% CI -1.7 to 1.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryAverage Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye

Time frame:: Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Mean · letters

Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye
letters	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline over the period Week 12 to 48	5.9 ± 11.45	6.5 ± 12.28	6.7 ± 11.27
Change from baseline over the period Week 12 to 96	5.9 ± 12.76	6.1 ± 13.21	6.5 ± 12.28

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.4 · 95% CI -2.0 to 1.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.1 · 95% CI -1.6 to 1.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -1.9 to 1.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.1 · 95% CI -1.7 to 1.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryAverage Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye

Time frame:: Baseline, Weeks 84, 88, 92, 96
Reported as:: Mean · letters

Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye
letters	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye	5.7 ± 15.15	5.7 ± 15.05	5.7 ± 14.29

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.4 · 95% CI -1.7 to 2.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.4 · 95% CI -1.7 to 2.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryPercentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	9.2 (6.4 to 12.7)	10.8 (7.8 to 14.5)	9.7 (6.9 to 13.3)
Change from baseline at Week 8	15.9 (12.3 to 20.1)	19.2 (15.2 to 23.6)	15.6 (12.0 to 19.7)
Change from baseline at Week 12	20.1 (16.1 to 24.6)	24.4 (20.1 to 29.2)	20.3 (16.2 to 24.8)
Change from baseline at Week 16	22.6 (18.4 to 27.3)	22.5 (18.3 to 27.2)	20.8 (16.8 to 25.4)
Change from baseline at Week 20	22.6 (18.4 to 27.3)	25.8 (21.4 to 30.7)	22.8 (18.5 to 27.5)
Change from baseline at Week 24	23.2 (18.9 to 27.9)	28.3 (23.7 to 33.3)	21.9 (17.8 to 26.6)
Change from baseline at Week 28	27.4 (22.8 to 32.3)	28.1 (23.5 to 33.0)	25.8 (21.4 to 30.7)
Change from baseline at Week 32	25.4 (21.0 to 30.3)	31.9 (27.2 to 37.0)	25.0 (20.6 to 29.8)
Change from baseline at Week 36	24.9 (20.5 to 29.7)	31.7 (26.9 to 36.7)	24.7 (20.4 to 29.5)
Change from baseline at Week 40	27.1 (22.6 to 32.0)	33.6 (28.7 to 38.7)	26.4 (21.9 to 31.3)
Change from baseline at Week 44	27.7 (23.1 to 32.6)	34.2 (29.3 to 39.3)	27.5 (23.0 to 32.4)
Change from baseline at Week 48	24.9 (20.5 to 29.7)	33.1 (28.2 to 38.2)	25.8 (21.4 to 30.7)
Change from baseline at Week 52	29.9 (25.2 to 34.9)	31.7 (26.9 to 36.7)	28.1 (23.5 to 33.0)
Change from baseline at Week 56	29.9 (25.2 to 34.9)	31.7 (26.9 to 36.7)	29.7 (25.0 to 34.7)
Change from baseline at Week 60	27.7 (23.1 to 32.6)	32.5 (27.7 to 37.6)	28.6 (24.0 to 33.6)
Change from baseline at Week 64	30.7 (26.0 to 35.8)	32.5 (27.7 to 37.6)	27.8 (23.2 to 32.7)
Change from baseline at Week 68	29.9 (25.2 to 34.9)	32.5 (27.7 to 37.6)	28.1 (23.5 to 33.0)
Change from baseline at Week 72	30.4 (25.7 to 35.5)	31.4 (26.6 to 36.5)	27.5 (23.0 to 32.4)
Change from baseline at Week 76	33.8 (28.9 to 39.0)	32.5 (27.7 to 37.6)	28.6 (24.0 to 33.6)
Change from baseline at Week 80	28.5 (23.9 to 33.5)	35.6 (30.6 to 40.7)	27.8 (23.2 to 32.7)
Change from baseline at Week 84	29.3 (24.7 to 34.3)	30.0 (25.3 to 35.0)	26.7 (22.2 to 31.6)
Change from baseline at Week 88	31.0 (26.2 to 36.1)	34.7 (29.8 to 39.9)	27.8 (23.2 to 32.7)
Change from baseline at Week 92	28.8 (24.1 to 33.8)	32.8 (27.9 to 37.9)	28.1 (23.5 to 33.0)
Change from baseline at Week 96	32.1 (27.3 to 37.2)	33.6 (28.7 to 38.7)	27.5 (23.0 to 32.4)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.2 · 95% CI -4.2 to 4.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.6 · 95% CI -2.8 to 5.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.8 · 95% CI -4.4 to 5.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.2 · 95% CI -1.2 to 10.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.2 · 95% CI -5.9 to 5.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.9 · 95% CI -0.5 to 11.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -3.7 to 8.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -3.8 to 8.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -5.9 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.8 · 95% CI -2.4 to 9.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -4.2 to 7.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 7.2 · 95% CI 0.8 to 13.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -4.3 to 8.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.2 · 95% CI -3.4 to 9.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -5.0 to 7.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 7.9 · 95% CI 1.5 to 14.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -5.4 to 7.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 8.1 · 95% CI 2.1 to 14.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.5 · 95% CI -4.4 to 8.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 8.3 · 95% CI 2.0 to 15.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -5.2 to 7.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 7.6 · 95% CI 0.7 to 13.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.2 · 95% CI -6.8 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 8.2 · 95% CI 2.2 to 15.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.8 · 95% CI -3.9 to 9.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.8 · 95% CI -1.5 to 11.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.8 · 95% CI -5.9 to 7.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.0 · 95% CI -3.1 to 9.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -6.5 to 6.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.9 · 95% CI -1.3 to 11.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.7 · 95% CI -2.9 to 10.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.8 · 95% CI -0.4 to 12.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.4 · 95% CI -4.2 to 9.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.6 · 95% CI -0.2 to 11.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.8 · 95% CI -3.0 to 9.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.1 · 95% CI -1.1 to 11.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 6.0 · 95% CI -1.5 to 12.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.0 · 95% CI -1.0 to 11.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -5.1 to 8.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 8.8 · 95% CI 2.7 to 15.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.3 · 95% CI -3.7 to 9.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.2 · 95% CI -2.2 to 10.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.1 · 95% CI -3.0 to 10.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 8.0 · 95% CI 1.9 to 14.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.6 · 95% CI -5.1 to 8.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.9 · 95% CI -0.0 to 12.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.5 · 95% CI -1.2 to 12.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 7.2 · 95% CI 1.4 to 13.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	19.3 (15.3 to 23.7)	24.4 (20.1 to 29.2)	19.2 (15.2 to 23.6)
Change from baseline at Week 8	30.7 (26.0 to 35.8)	32.5 (27.7 to 37.6)	32.2 (27.4 to 37.3)
Change from baseline at Week 12	33.2 (28.4 to 38.4)	38.6 (33.6 to 43.9)	33.9 (29.0 to 39.0)
Change from baseline at Week 16	35.2 (30.2 to 40.4)	39.7 (34.6 to 45.0)	35.6 (30.6 to 40.7)
Change from baseline at Week 20	37.2 (32.1 to 42.4)	42.2 (37.1 to 47.5)	38.3 (33.3 to 43.6)
Change from baseline at Week 24	40.2 (35.1 to 45.5)	41.9 (36.8 to 47.2)	39.4 (34.4 to 44.7)
Change from baseline at Week 28	41.1 (35.9 to 46.4)	43.9 (38.7 to 49.2)	41.4 (36.3 to 46.7)
Change from baseline at Week 32	38.3 (33.2 to 43.5)	43.9 (38.7 to 49.2)	41.7 (36.5 to 46.9)
Change from baseline at Week 36	41.1 (35.9 to 46.4)	43.3 (38.1 to 48.6)	43.1 (37.9 to 48.3)
Change from baseline at Week 40	41.3 (36.2 to 46.6)	45.3 (40.1 to 50.6)	44.2 (39.0 to 49.5)
Change from baseline at Week 44	44.4 (39.2 to 49.7)	43.1 (37.9 to 48.3)	44.2 (39.0 to 49.5)
Change from baseline at Week 48	41.3 (36.2 to 46.6)	45.3 (40.1 to 50.6)	44.2 (39.0 to 49.5)
Change from baseline at Week 52	43.0 (37.8 to 48.3)	43.9 (38.7 to 49.2)	44.2 (39.0 to 49.5)
Change from baseline at Week 56	44.4 (39.2 to 49.7)	42.5 (37.3 to 47.8)	45.3 (40.1 to 50.6)
Change from baseline at Week 60	41.6 (36.5 to 46.9)	45.6 (40.3 to 50.9)	43.6 (38.4 to 48.9)
Change from baseline at Week 64	43.0 (37.8 to 48.3)	44.7 (39.5 to 50.0)	40.6 (35.4 to 45.8)
Change from baseline at Week 68	44.7 (39.5 to 50.0)	44.2 (39.0 to 49.5)	43.6 (38.4 to 48.9)
Change from baseline at Week 72	45.3 (40.0 to 50.6)	41.9 (36.8 to 47.2)	41.9 (36.8 to 47.2)
Change from baseline at Week 76	45.0 (39.7 to 50.3)	44.4 (39.2 to 49.7)	44.4 (39.2 to 49.7)
Change from baseline at Week 80	41.3 (36.2 to 46.6)	43.6 (38.4 to 48.9)	43.3 (38.1 to 48.6)
Change from baseline at Week 84	43.3 (38.1 to 48.6)	42.8 (37.6 to 48.1)	42.2 (37.1 to 47.5)
Change from baseline at Week 88	44.4 (39.2 to 49.7)	43.6 (38.4 to 48.9)	41.7 (36.5 to 46.9)
Change from baseline at Week 92	44.1 (38.9 to 49.4)	43.3 (38.1 to 48.6)	40.8 (35.7 to 46.1)
Change from baseline at Week 96	43.6 (38.4 to 48.9)	43.9 (38.7 to 49.2)	39.7 (34.6 to 45.0)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.3 · 95% CI -4.3 to 6.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 6.3 · 95% CI 0.6 to 12.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -6.6 to 6.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -4.7 to 8.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.5 · 95% CI -6.2 to 7.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 6.0 · 95% CI -0.8 to 12.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -6.0 to 7.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.6 · 95% CI -1.5 to 12.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -6.5 to 7.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.2 · 95% CI -1.8 to 12.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.5 · 95% CI -4.0 to 9.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.8 · 95% CI -3.5 to 11.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -5.9 to 8.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.9 · 95% CI -3.4 to 11.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.6 · 95% CI -8.2 to 5.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.6 · 95% CI -3.2 to 10.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -7.3 to 6.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -5.2 to 8.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.9 · 95% CI -7.8 to 6.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -4.8 to 10.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.2 · 95% CI -4.4 to 9.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.2 · 95% CI -7.1 to 7.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.0 · 95% CI -7.9 to 6.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.4 · 95% CI -4.5 to 9.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.5 · 95% CI -6.8 to 8.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -5.8 to 8.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -6.1 to 8.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.3 · 95% CI -8.6 to 5.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -7.0 to 7.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.4 · 95% CI -3.5 to 11.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.0 · 95% CI -3.0 to 10.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.5 · 95% CI -1.4 to 13.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.7 · 95% CI -4.1 to 9.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -4.8 to 9.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.2 · 95% CI -1.6 to 12.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.6 · 95% CI -5.4 to 8.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.5 · 95% CI -4.8 to 9.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.5 · 95% CI -5.0 to 8.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -6.9 to 7.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -5.1 to 8.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.0 · 95% CI -3.9 to 10.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -5.0 to 9.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.6 · 95% CI -2.5 to 11.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.3 · 95% CI -3.4 to 10.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.1 · 95% CI -1.6 to 12.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.9 · 95% CI -3.0 to 11.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.6 · 95% CI -1.9 to 12.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.7 · 95% CI -1.0 to 12.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	40.2 (35.1 to 45.5)	43.3 (38.1 to 48.6)	43.1 (37.9 to 48.3)
Change from baseline at Week 8	54.2 (48.9 to 59.4)	53.1 (47.8 to 58.3)	56.1 (50.8 to 61.3)
Change from baseline at Week 12	54.7 (49.4 to 60.0)	58.6 (53.3 to 63.7)	57.8 (52.5 to 62.9)
Change from baseline at Week 16	54.7 (49.4 to 60.0)	59.2 (53.9 to 64.3)	58.6 (53.3 to 63.7)
Change from baseline at Week 20	57.5 (52.2 to 62.7)	56.9 (51.7 to 62.1)	62.2 (57.0 to 67.3)
Change from baseline at Week 24	59.2 (53.9 to 64.4)	63.1 (57.8 to 68.1)	61.7 (56.4 to 66.7)
Change from baseline at Week 28	60.1 (54.8 to 65.2)	61.7 (56.4 to 66.7)	61.7 (56.4 to 66.7)
Change from baseline at Week 32	60.1 (54.8 to 65.2)	61.7 (56.4 to 66.7)	59.7 (54.5 to 64.8)
Change from baseline at Week 36	58.1 (52.8 to 63.3)	59.2 (53.9 to 64.3)	65.8 (60.7 to 70.7)
Change from baseline at Week 40	60.1 (54.8 to 65.2)	63.1 (57.8 to 68.1)	63.1 (57.8 to 68.1)
Change from baseline at Week 44	60.9 (55.6 to 66.0)	62.5 (57.3 to 67.5)	65.6 (60.4 to 70.5)
Change from baseline at Week 48	59.2 (53.9 to 64.4)	61.1 (55.9 to 66.2)	65.6 (60.4 to 70.5)
Change from baseline at Week 52	61.5 (56.2 to 66.5)	60.6 (55.3 to 65.6)	64.2 (59.0 to 69.1)
Change from baseline at Week 56	62.3 (57.0 to 67.3)	60.8 (55.6 to 65.9)	62.2 (57.0 to 67.3)
Change from baseline at Week 60	61.7 (56.5 to 66.8)	60.6 (55.3 to 65.6)	61.9 (56.7 to 67.0)
Change from baseline at Week 64	59.5 (54.2 to 64.6)	61.4 (56.1 to 66.4)	61.9 (56.7 to 67.0)
Change from baseline at Week 68	61.2 (55.9 to 66.3)	60.3 (55.0 to 65.4)	64.7 (59.5 to 69.7)
Change from baseline at Week 72	59.8 (54.5 to 64.9)	60.6 (55.3 to 65.6)	60.0 (54.7 to 65.1)
Change from baseline at Week 76	60.3 (55.1 to 65.4)	60.3 (55.0 to 65.4)	59.7 (54.5 to 64.8)
Change from baseline at Week 80	60.1 (54.8 to 65.2)	58.1 (52.8 to 63.2)	58.3 (53.1 to 63.5)
Change from baseline at Week 84	58.9 (53.6 to 64.1)	58.6 (53.3 to 63.7)	58.6 (53.3 to 63.7)
Change from baseline at Week 88	58.9 (53.6 to 64.1)	57.8 (52.5 to 62.9)	61.7 (56.4 to 66.7)
Change from baseline at Week 92	59.2 (53.9 to 64.4)	58.3 (53.1 to 63.5)	61.4 (56.1 to 66.4)
Change from baseline at Week 96	61.7 (56.5 to 66.8)	58.1 (52.8 to 63.2)	58.6 (53.3 to 63.7)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -7.7 to 6.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -5.3 to 8.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -7.4 to 6.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.8 · 95% CI -8.9 to 5.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.4 · 95% CI -8.1 to 5.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -4.8 to 8.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.4 · 95% CI -9.8 to 4.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.5 · 95% CI -5.3 to 8.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.1 · 95% CI -9.7 to 3.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.1 · 95% CI -11.4 to 3.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.9 · 95% CI -7.6 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.5 · 95% CI -4.4 to 10.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.2 · 95% CI -7.2 to 6.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -6.3 to 7.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.0 · 95% CI -4.7 to 9.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.1 · 95% CI -3.9 to 10.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.0 · 95% CI -12.6 to 1.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.4 · 95% CI -12.7 to 1.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.6 · 95% CI -8.1 to 5.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -6.2 to 7.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.0 · 95% CI -9.6 to 3.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.0 · 95% CI -9.1 to 5.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.6 · 95% CI -11.1 to 2.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.5 · 95% CI -10.4 to 3.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.0 · 95% CI -8.0 to 5.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.7 · 95% CI -9.7 to 4.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -5.5 to 7.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -7.2 to 6.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -5.8 to 8.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -7.2 to 6.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.0 · 95% CI -7.9 to 5.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.5 · 95% CI -6.6 to 7.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.1 · 95% CI -9.4 to 5.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.1 · 95% CI -10.0 to 4.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -6.2 to 8.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -5.5 to 9.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.4 · 95% CI -5.1 to 9.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -5.0 to 8.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.2 · 95% CI -3.9 to 10.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.8 · 95% CI -6.1 to 8.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -5.1 to 8.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.3 · 95% CI -5.9 to 8.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.2 · 95% CI -8.5 to 5.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.5 · 95% CI -9.7 to 4.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.4 · 95% CI -7.9 to 6.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.1 · 95% CI -9.1 to 5.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.6 · 95% CI -2.9 to 11.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -6.6 to 8.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	1.7 (0.6 to 3.6)	3.1 (1.5 to 5.4)	1.4 (0.5 to 3.2)
Change from baseline at Week 8	1.7 (0.6 to 3.6)	2.8 (1.3 to 5.0)	2.2 (1.0 to 4.3)
Change from baseline at Week 12	3.4 (1.7 to 5.8)	3.6 (1.9 to 6.1)	3.9 (2.1 to 6.4)
Change from baseline at Week 16	3.1 (1.5 to 5.4)	3.6 (1.9 to 6.1)	3.3 (1.7 to 5.8)
Change from baseline at Week 20	2.5 (1.2 to 4.7)	4.7 (2.8 to 7.5)	2.5 (1.1 to 4.7)
Change from baseline at Week 24	4.2 (2.4 to 6.8)	5.3 (3.2 to 8.1)	3.9 (2.1 to 6.4)
Change from baseline at Week 28	4.7 (2.8 to 7.5)	5.6 (3.4 to 8.4)	4.4 (2.6 to 7.1)
Change from baseline at Week 32	5.3 (3.2 to 8.2)	6.4 (4.1 to 9.4)	4.2 (2.4 to 6.8)
Change from baseline at Week 36	4.7 (2.8 to 7.5)	6.4 (4.1 to 9.4)	3.3 (1.7 to 5.8)
Change from baseline at Week 40	5.0 (3.0 to 7.8)	6.9 (4.5 to 10.1)	4.2 (2.4 to 6.8)
Change from baseline at Week 44	5.6 (3.4 to 8.5)	6.4 (4.1 to 9.4)	4.4 (2.6 to 7.1)
Change from baseline at Week 48	5.9 (3.7 to 8.8)	6.4 (4.1 to 9.4)	5.6 (3.4 to 8.4)
Change from baseline at Week 52	6.1 (3.9 to 9.2)	6.9 (4.5 to 10.1)	5.8 (3.6 to 8.8)
Change from baseline at Week 56	6.4 (4.1 to 9.5)	7.8 (5.2 to 11.0)	5.3 (3.2 to 8.1)
Change from baseline at Week 60	5.9 (3.7 to 8.8)	6.9 (4.5 to 10.1)	5.8 (3.6 to 8.8)
Change from baseline at Week 64	7.3 (4.8 to 10.5)	8.6 (5.9 to 12.0)	5.8 (3.6 to 8.8)
Change from baseline at Week 68	7.3 (4.8 to 10.5)	7.5 (5.0 to 10.7)	6.4 (4.1 to 9.4)
Change from baseline at Week 72	7.3 (4.8 to 10.5)	7.5 (5.0 to 10.7)	6.1 (3.9 to 9.1)
Change from baseline at Week 76	6.7 (4.3 to 9.8)	8.1 (5.5 to 11.4)	6.1 (3.9 to 9.1)
Change from baseline at Week 80	7.3 (4.8 to 10.5)	7.8 (5.2 to 11.0)	8.1 (5.5 to 11.4)
Change from baseline at Week 84	8.7 (6.0 to 12.1)	7.8 (5.2 to 11.0)	7.2 (4.8 to 10.4)
Change from baseline at Week 88	8.7 (6.0 to 12.1)	8.1 (5.5 to 11.4)	8.1 (5.5 to 11.4)
Change from baseline at Week 92	8.7 (6.0 to 12.1)	8.1 (5.5 to 11.4)	6.9 (4.5 to 10.1)
Change from baseline at Week 96	8.7 (6.0 to 12.1)	8.1 (5.5 to 11.4)	7.5 (5.0 to 10.7)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.4 · 95% CI -1.4 to 2.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -0.5 to 4.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -2.6 to 1.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.7 · 95% CI -1.7 to 2.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -3.3 to 2.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -3.2 to 2.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -3.0 to 2.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -2.4 to 3.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.0 · 95% CI -2.2 to 2.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -0.3 to 5.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -2.6 to 3.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.5 · 95% CI -1.8 to 4.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.2 · 95% CI -2.9 to 3.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -2.3 to 4.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -2.0 to 4.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.2 · 95% CI -1.0 to 5.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -1.5 to 4.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.1 · 95% CI 0.0 to 6.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -2.1 to 3.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.8 · 95% CI -0.7 to 6.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -2.2 to 4.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.0 · 95% CI -1.4 to 5.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -3.2 to 3.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -2.7 to 4.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -3.3 to 4.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.3 · 95% CI -2.5 to 4.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -2.4 to 4.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.6 · 95% CI -1.5 to 6.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.1 · 95% CI -3.5 to 3.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -2.9 to 4.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.5 · 95% CI -2.4 to 5.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.8 · 95% CI -1.3 to 6.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.8 · 95% CI -3.1 to 4.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -2.9 to 4.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -2.6 to 4.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.5 · 95% CI -2.7 to 5.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.1 to 4.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.0 · 95% CI -2.1 to 6.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -4.8 to 3.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.2 · 95% CI -4.6 to 3.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -2.6 to 5.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.7 to 4.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.7 to 4.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.1 · 95% CI -4.1 to 4.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -2.2 to 5.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -3.0 to 5.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -2.9 to 4.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.7 · 95% CI -3.6 to 4.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	3.6 (1.9 to 6.1)	4.4 (2.6 to 7.1)	4.2 (2.4 to 6.8)
Change from baseline at Week 8	3.4 (1.7 to 5.8)	3.9 (2.1 to 6.4)	3.9 (2.1 to 6.4)
Change from baseline at Week 12	4.7 (2.8 to 7.5)	5.8 (3.6 to 8.8)	5.8 (3.6 to 8.8)
Change from baseline at Week 16	5.0 (3.0 to 7.8)	4.2 (2.4 to 6.8)	5.6 (3.4 to 8.4)
Change from baseline at Week 20	4.5 (2.6 to 7.2)	6.4 (4.1 to 9.4)	5.3 (3.2 to 8.1)
Change from baseline at Week 24	5.9 (3.7 to 8.8)	8.6 (5.9 to 12.0)	6.4 (4.1 to 9.4)
Change from baseline at Week 28	7.8 (5.3 to 11.1)	7.8 (5.2 to 11.0)	7.2 (4.8 to 10.4)
Change from baseline at Week 32	7.8 (5.3 to 11.1)	7.8 (5.2 to 11.0)	7.2 (4.8 to 10.4)
Change from baseline at Week 36	8.4 (5.7 to 11.7)	8.9 (6.2 to 12.3)	6.9 (4.5 to 10.1)
Change from baseline at Week 40	8.1 (5.5 to 11.4)	9.2 (6.4 to 12.6)	8.3 (5.7 to 11.7)
Change from baseline at Week 44	8.7 (6.0 to 12.1)	8.6 (5.9 to 12.0)	8.1 (5.5 to 11.4)
Change from baseline at Week 48	9.5 (6.7 to 13.0)	8.9 (6.2 to 12.3)	7.5 (5.0 to 10.7)
Change from baseline at Week 52	8.9 (6.2 to 12.4)	11.1 (8.1 to 14.8)	8.3 (5.7 to 11.7)
Change from baseline at Week 56	9.8 (6.9 to 13.3)	10.3 (7.3 to 13.9)	7.8 (5.2 to 11.0)
Change from baseline at Week 60	8.9 (6.2 to 12.4)	10.6 (7.6 to 14.2)	9.4 (6.6 to 12.9)
Change from baseline at Week 64	10.6 (7.6 to 14.3)	11.1 (8.1 to 14.8)	9.2 (6.4 to 12.6)
Change from baseline at Week 68	10.3 (7.4 to 14.0)	11.4 (8.3 to 15.1)	9.2 (6.4 to 12.6)
Change from baseline at Week 72	10.3 (7.4 to 14.0)	11.1 (8.1 to 14.8)	12.2 (9.0 to 16.1)
Change from baseline at Week 76	8.9 (6.2 to 12.4)	12.2 (9.0 to 16.1)	10.0 (7.1 to 13.6)
Change from baseline at Week 80	9.8 (6.9 to 13.3)	12.5 (9.3 to 16.4)	10.8 (7.8 to 14.5)
Change from baseline at Week 84	11.5 (8.3 to 15.2)	12.8 (9.5 to 16.7)	10.8 (7.8 to 14.5)
Change from baseline at Week 88	11.7 (8.6 to 15.5)	12.2 (9.0 to 16.1)	12.2 (9.0 to 16.1)
Change from baseline at Week 92	11.5 (8.3 to 15.2)	11.7 (8.5 to 15.4)	11.9 (8.8 to 15.8)
Change from baseline at Week 96	12.0 (8.8 to 15.8)	14.7 (11.2 to 18.8)	12.5 (9.3 to 16.4)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.7 · 95% CI -3.7 to 2.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -2.6 to 3.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -3.3 to 2.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.0 · 95% CI -3.0 to 2.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.2 · 95% CI -4.6 to 2.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.1 · 95% CI -3.5 to 3.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -4.2 to 2.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.5 · 95% CI -5.0 to 2.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.9 · 95% CI -4.1 to 2.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -2.3 to 4.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -3.9 to 3.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -1.8 to 6.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.5 · 95% CI -3.5 to 4.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.6 to 4.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.2 to 4.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.2 to 4.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -2.6 to 5.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -2.1 to 5.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.2 · 95% CI -4.3 to 3.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.8 · 95% CI -3.6 to 4.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.7 to 4.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.7 · 95% CI -3.7 to 4.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -2.2 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.3 · 95% CI -2.9 to 5.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -3.5 to 4.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.0 · 95% CI -1.6 to 7.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.0 · 95% CI -2.3 to 6.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.5 · 95% CI -2.2 to 6.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.4 · 95% CI -4.8 to 3.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -3.8 to 5.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -3.1 to 5.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.0 · 95% CI -2.8 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -3.4 to 5.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -2.8 to 6.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.9 · 95% CI -6.6 to 2.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.9 · 95% CI -6.1 to 3.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.1 · 95% CI -5.6 to 3.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -2.9 to 6.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.2 · 95% CI -5.8 to 3.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -3.2 to 6.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.5 · 95% CI -4.2 to 5.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -3.2 to 6.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -5.8 to 4.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.1 · 95% CI -5.2 to 4.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -5.5 to 4.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.2 · 95% CI -5.3 to 4.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -5.7 to 4.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -3.4 to 7.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	9.8 (6.9 to 13.3)	10.3 (7.3 to 13.9)	7.8 (5.2 to 11.0)
Change from baseline at Week 8	7.5 (5.0 to 10.8)	10.3 (7.3 to 13.9)	7.5 (5.0 to 10.7)
Change from baseline at Week 12	10.3 (7.4 to 14.0)	11.9 (8.8 to 15.8)	8.3 (5.7 to 11.7)
Change from baseline at Week 16	10.3 (7.4 to 14.0)	9.4 (6.6 to 12.9)	10.8 (7.8 to 14.5)
Change from baseline at Week 20	8.7 (6.0 to 12.1)	11.9 (8.8 to 15.8)	10.0 (7.1 to 13.6)
Change from baseline at Week 24	10.3 (7.4 to 14.0)	15.0 (11.5 to 19.1)	11.1 (8.1 to 14.8)
Change from baseline at Week 28	10.6 (7.6 to 14.3)	13.6 (10.2 to 17.6)	12.8 (9.5 to 16.7)
Change from baseline at Week 32	12.8 (9.6 to 16.8)	12.2 (9.0 to 16.1)	13.3 (10.0 to 17.3)
Change from baseline at Week 36	14.0 (10.5 to 18.0)	13.1 (9.8 to 17.0)	10.8 (7.8 to 14.5)
Change from baseline at Week 40	12.0 (8.8 to 15.8)	13.6 (10.2 to 17.6)	13.1 (9.8 to 17.0)
Change from baseline at Week 44	13.7 (10.3 to 17.7)	12.8 (9.5 to 16.7)	14.4 (11.0 to 18.5)
Change from baseline at Week 48	13.7 (10.3 to 17.7)	12.5 (9.3 to 16.4)	11.7 (8.5 to 15.4)
Change from baseline at Week 52	14.0 (10.5 to 18.0)	15.0 (11.5 to 19.1)	13.6 (10.2 to 17.6)
Change from baseline at Week 56	13.4 (10.1 to 17.4)	13.9 (10.5 to 17.9)	12.5 (9.3 to 16.4)
Change from baseline at Week 60	13.7 (10.3 to 17.7)	15.0 (11.5 to 19.1)	13.3 (10.0 to 17.3)
Change from baseline at Week 64	15.4 (11.8 to 19.5)	16.1 (12.5 to 20.3)	13.3 (10.0 to 17.3)
Change from baseline at Week 68	14.2 (10.8 to 18.3)	15.3 (11.7 to 19.4)	14.7 (11.2 to 18.8)
Change from baseline at Week 72	15.9 (12.3 to 20.1)	15.0 (11.5 to 19.1)	14.7 (11.2 to 18.8)
Change from baseline at Week 76	15.9 (12.3 to 20.1)	16.1 (12.5 to 20.3)	15.0 (11.5 to 19.1)
Change from baseline at Week 80	16.2 (12.5 to 20.4)	16.7 (13.0 to 20.9)	15.6 (12.0 to 19.7)
Change from baseline at Week 84	17.9 (14.0 to 22.2)	19.2 (15.2 to 23.6)	15.8 (12.2 to 20.0)
Change from baseline at Week 88	17.0 (13.3 to 21.3)	17.5 (13.7 to 21.8)	16.1 (12.5 to 20.3)
Change from baseline at Week 92	17.3 (13.5 to 21.6)	17.5 (13.7 to 21.8)	16.1 (12.5 to 20.3)
Change from baseline at Week 96	20.4 (16.3 to 24.9)	18.9 (15.0 to 23.3)	17.2 (13.5 to 21.5)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.6 · 95% CI -2.4 to 5.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.4 · 95% CI -1.8 to 6.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.2 · 95% CI -4.1 to 3.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.7 · 95% CI -1.7 to 6.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.8 · 95% CI -2.3 to 6.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.4 · 95% CI -0.9 to 7.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.7 · 95% CI -5.4 to 4.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.6 · 95% CI -6.2 to 3.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.3 · 95% CI -5.4 to 3.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.0 · 95% CI -2.9 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -5.2 to 3.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.8 · 95% CI -1.4 to 8.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.3 · 95% CI -6.8 to 2.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.8 · 95% CI -4.7 to 5.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -5.0 to 4.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.1 · 95% CI -6.1 to 4.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.8 · 95% CI -1.8 to 7.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -2.7 to 6.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.1 · 95% CI -5.9 to 4.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.4 · 95% CI -4.7 to 4.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.7 · 95% CI -5.7 to 4.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.6 · 95% CI -6.5 to 3.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -2.7 to 6.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.8 · 95% CI -4.3 to 5.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.2 · 95% CI -4.6 to 5.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.6 · 95% CI -3.9 to 6.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -4.0 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.5 · 95% CI -3.8 to 6.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.4 · 95% CI -4.5 to 5.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -3.8 to 6.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.2 · 95% CI -2.9 to 7.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.9 · 95% CI -2.8 to 7.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -5.5 to 4.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.5 · 95% CI -5.1 to 5.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -4.3 to 6.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.5 · 95% CI -5.2 to 5.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -4.6 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -4.7 to 6.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.7 · 95% CI -4.8 to 6.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -4.8 to 6.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.2 · 95% CI -3.1 to 7.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.3 · 95% CI -2.9 to 8.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -4.5 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -4.6 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.3 · 95% CI -4.5 to 6.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.4 · 95% CI -4.5 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.8 · 95% CI -3.1 to 8.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.6 · 95% CI -4.7 to 7.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly (0-100 letters). A score of 65 to 70 letters represents a low to moderate visual acuity. Baseline was defined as the last measurement prior to first treatment. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Baseline	24.9 (20.5 to 29.7)	21.7 (17.5 to 26.3)	19.2 (15.2 to 23.6)
Week 4	34.6 (29.7 to 39.8)	33.3 (28.5 to 38.5)	33.9 (29.0 to 39.0)
Week 8	42.5 (37.3 to 47.8)	42.8 (37.6 to 48.1)	42.8 (37.6 to 48.1)
Week 12	45.3 (40.0 to 50.6)	43.9 (38.7 to 49.2)	45.8 (40.6 to 51.1)
Week 16	46.4 (41.1 to 51.7)	46.7 (41.4 to 52.0)	44.4 (39.2 to 49.7)
Week 20	46.4 (41.1 to 51.7)	46.9 (41.7 to 52.2)	48.1 (42.8 to 53.4)
Week 24	49.7 (44.4 to 55.0)	47.8 (42.5 to 53.1)	46.4 (41.1 to 51.7)
Week 28	48.9 (43.6 to 54.2)	49.7 (44.4 to 55.0)	46.9 (41.7 to 52.2)
Week 32	48.0 (42.8 to 53.4)	51.4 (46.1 to 56.7)	44.4 (39.2 to 49.7)
Week 36	47.8 (42.5 to 53.1)	50.6 (45.3 to 55.8)	48.3 (43.1 to 53.6)
Week 40	51.7 (46.4 to 57.0)	49.2 (43.9 to 54.5)	48.6 (43.3 to 53.9)
Week 44	49.7 (44.4 to 55.0)	50.0 (44.7 to 55.3)	50.3 (45.0 to 55.6)
Week 48	49.7 (44.4 to 55.0)	50.6 (45.3 to 55.8)	50.8 (45.5 to 56.1)
Week 52	48.6 (43.3 to 53.9)	50.6 (45.3 to 55.8)	49.2 (43.9 to 54.5)
Week 56	50.8 (45.5 to 56.1)	50.0 (44.7 to 55.3)	48.6 (43.3 to 53.9)
Week 60	52.0 (46.6 to 57.2)	48.1 (42.8 to 53.4)	49.2 (43.9 to 54.5)
Week 64	50.8 (45.5 to 56.1)	50.6 (45.3 to 55.8)	49.2 (43.9 to 54.5)
Week 68	50.6 (45.3 to 55.9)	48.3 (43.1 to 53.6)	46.7 (41.4 to 52.0)
Week 72	50.8 (45.5 to 56.1)	49.2 (43.9 to 54.5)	49.4 (44.2 to 54.7)
Week 76	52.2 (46.9 to 57.5)	49.2 (43.9 to 54.5)	46.1 (40.9 to 51.4)
Week 80	51.4 (46.1 to 56.7)	49.7 (44.4 to 55.0)	45.6 (40.3 to 50.9)
Week 84	50.6 (45.3 to 55.9)	47.2 (42.0 to 52.5)	45.3 (40.1 to 50.6)
Week 88	50.6 (45.3 to 55.9)	50.3 (45.0 to 55.6)	48.6 (43.3 to 53.9)
Week 92	51.7 (46.4 to 57.0)	49.4 (44.2 to 54.7)	45.8 (40.6 to 51.1)
Week 96	48.9 (43.6 to 54.2)	49.4 (44.2 to 54.7)	45.6 (40.3 to 50.9)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.1 · 95% CI -7.7 to 3.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.7 · 95% CI -8.5 to 2.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.0 · 95% CI -8.9 to 2.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.1 · 95% CI -7.7 to 3.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.1 · 95% CI -8.9 to 2.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.0 · 95% CI -10.0 to 2.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -6.3 to 5.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.1 · 95% CI -6.2 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.0 · 95% CI -10.4 to 2.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.4 · 95% CI -9.4 to 2.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -4.6 to 6.9Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -6.6 to 5.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -6.5 to 5.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -4.9 to 7.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.6 · 95% CI -3.9 to 7.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.1 · 95% CI -1.0 to 11.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.4 · 95% CI -8.5 to 3.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.4 · 95% CI -6.0 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -5.2 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.2 · 95% CI -7.4 to 5.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.4 · 95% CI -8.8 to 3.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.2 · 95% CI -8.4 to 4.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.5 · 95% CI -9.5 to 2.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.4 · 95% CI -8.6 to 3.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.4 · 95% CI -8.8 to 3.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -6.8 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.2 · 95% CI -5.9 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -6.6 to 6.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.6 · 95% CI -5.7 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.0 · 95% CI -9.0 to 3.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -7.2 to 5.5
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -6.6 to 5.7Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.0 · 95% CI -4.3 to 8.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -6.3 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.4 · 95% CI -7.2 to 5.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.1 · 95% CI -8.5 to 4.3Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.0 · 95% CI -2.4 to 10.2Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.2 · 95% CI -5.1 to 7.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.9 · 95% CI -2.5 to 9.6Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.4 · 95% CI -3.5 to 9.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.3 · 95% CI -3.0 to 9.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.2 · 95% CI -5.8 to 6.4Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.0 · 95% CI -6.6 to 6.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -6.0 to 6.1Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.8 · 95% CI -2.8 to 9.5Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.8 · 95% CI -4.3 to 8.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -4.7 to 7.8Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -3.8 to 9.0Statistical model used logistic regression adjusting for BCVA categories, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryChange From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye

CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Spectral-Domain Optical Coherence Tomography (SD-OCT), a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Mean · micrometers

Change From Baseline in Central Subfield Thickness (CSFTtot) at Each Post-baseline Visit - Study Eye
micrometers	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	-142.2 ± 130.54	-150.9 ± 120.85	-137.8 ± 120.62
Change from baseline at Week 8	-163.7 ± 139.68	-169.1 ± 132.62	-154.3 ± 126.05
Change from baseline at Week 12	-172.5 ± 142.82	-177.6 ± 137.13	-157.3 ± 125.86
Change from baseline at Week 16	-151.4 ± 145.66	-159.6 ± 133.91	-135.3 ± 132.50
Change from baseline at Week 20	-151.5 ± 142.70	-153.8 ± 144.23	-161.1 ± 128.75
Change from baseline at Week 24	-160.4 ± 151.33	-164.6 ± 141.67	-138.9 ± 136.02
Change from baseline at Week 28	-169.1 ± 147.81	-169.7 ± 146.82	-161.8 ± 133.79
Change from baseline at Week 32	-153.9 ± 154.59	-157.0 ± 144.46	-137.5 ± 142.15
Change from baseline at Week 36	-173.0 ± 150.80	-175.3 ± 147.18	-160.2 ± 137.94
Change from baseline at Week 40	-164.3 ± 153.85	-166.9 ± 141.94	-141.1 ± 144.80
Change from baseline at Week 44	-165.1 ± 151.34	-167.4 ± 156.10	-160.3 ± 139.14
Change from baseline at Week 48	-165.3 ± 152.86	-170.9 ± 142.48	-145.6 ± 145.53
Change from baseline at Week 52	-174.4 ± 149.06	-173.8 ± 149.18	-162.9 ± 141.57
Change from baseline at Week 56	-161.7 ± 148.33	-161.6 ± 149.26	-145.5 ± 145.95
Change from baseline at Week 60	-177.4 ± 150.58	-171.3 ± 152.35	-162.8 ± 143.92
Change from baseline at Week 64	-170.8 ± 160.61	-166.2 ± 148.96	-147.6 ± 145.88
Change from baseline at Week 68	-171.7 ± 149.54	-169.8 ± 151.91	-160.6 ± 150.34
Change from baseline at Week 72	-173.0 ± 152.01	-169.5 ± 149.17	-146.8 ± 151.89
Change from baseline at Week 76	-176.6 ± 154.87	-172.9 ± 153.90	-161.4 ± 147.50
Change from baseline at Week 80	-168.4 ± 157.11	-167.1 ± 152.62	-147.2 ± 156.73
Change from baseline at Week 84	-181.7 ± 152.44	-173.9 ± 157.54	-166.4 ± 151.94
Change from baseline at Week 88	-174.3 ± 154.83	-171.1 ± 152.31	-150.9 ± 157.20
Change from baseline at Week 92	-176.9 ± 154.63	-174.1 ± 157.30	-165.8 ± 150.35
Change from baseline at Week 96	-177.8 ± 155.03	-172.9 ± 156.38	-150.7 ± 154.86

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -7.9 · 95% CI -24.2 to 8.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -16.5 · 95% CI -31.9 to -1.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -13.7 · 95% CI -30.4 to 3.0Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -19.0 · 95% CI -35.0 to -2.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -19.7 · 95% CI -36.3 to -3.1Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -24.5 · 95% CI -40.7 to -8.3Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · p = 0.0159 (1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg) · Least squares mean difference: -19.9 · 95% CI -38.0 to -1.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · p = 0.0008 (1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg) · Least squares mean difference: -27.8 · 95% CI -45.1 to -10.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 5.2 · 95% CI -11.8 to 22.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 3.2 · 95% CI -14.1 to 20.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -25.8 · 95% CI -44.3 to -7.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -29.6 · 95% CI -47.5 to -11.6Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -11.6 · 95% CI -29.2 to 5.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -12.1 · 95% CI -29.8 to 5.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -20.1 · 95% CI -39.6 to -0.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -23.2 · 95% CI -42.1 to -4.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -17.4 · 95% CI -35.5 to 0.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -19.6 · 95% CI -37.6 to -1.7Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -27.3 · 95% CI -46.6 to -8.0Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -29.5 · 95% CI -48.2 to -10.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -9.3 · 95% CI -27.5 to 8.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -11.4 · 95% CI -30.3 to 7.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · p = 0.0075 (1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg) · Least squares mean difference: -23.9 · 95% CI -43.1 to -4.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · p = 0.0012 (1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg) · Least squares mean difference: -29.0 · 95% CI -47.6 to -10.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -15.6 · 95% CI -33.6 to 2.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -15.1 · 95% CI -33.4 to 3.3Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -20.0 · 95% CI -38.9 to -1.1Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -20.0 · 95% CI -39.4 to -0.7Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -18.8 · 95% CI -37.0 to -0.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -12.7 · 95% CI -31.4 to 6.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -27.2 · 95% CI -46.7 to -7.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -22.5 · 95% CI -41.6 to -3.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -14.9 · 95% CI -33.8 to 3.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -13.2 · 95% CI -32.6 to 6.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -29.9 · 95% CI -49.3 to -10.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -26.4 · 95% CI -46.0 to -6.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -19.3 · 95% CI -38.2 to -0.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -15.7 · 95% CI -35.0 to 3.7Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -24.8 · 95% CI -45.0 to -4.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -23.7 · 95% CI -43.9 to -3.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -19.5 · 95% CI -38.4 to -0.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -11.8 · 95% CI -31.5 to 8.0Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -27.3 · 95% CI -47.3 to -7.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -24.2 · 95% CI -44.3 to -4.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -15.1 · 95% CI -34.2 to 3.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -12.5 · 95% CI -32.1 to 7.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -30.9 · 95% CI -50.6 to -11.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -26.0 · 95% CI -46.2 to -5.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryAverage Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye

CSFTtot (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Time frame:: Baseline, Weeks 36, 40, 44, 48
Reported as:: Mean · micrometers

Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye
micrometers	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Average Change From Baseline in CSFTtot Over the Period Week 36 Through Week 48 - Study Eye	-166.9 ± 148.90	-170.1 ± 143.48	-151.8 ± 139.53

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · p = 0.0183 (1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg) · Least squares mean difference: -19.5 · 95% CI -37.7 to -1.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · p = 0.0075 (1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg) · Least squares mean difference: -22.4 · 95% CI -40.4 to -4.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryAverage Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye

Time frame:: Baseline, Weeks 84, 88, 92, 96
Reported as:: Mean · micrometers

Average Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye
micrometers	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Average Change From Baseline in CSFTtot Over the Period Week 84 Through Week 96 - Study Eye	-177.7 ± 153.15	-173.0 ± 154.47	-158.4 ± 151.86

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -23.2 · 95% CI -42.4 to -4.1Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -18.6 · 95% CI -38.3 to 1.0Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryAverage Change From Baseline in CSFTtot Over the Period Week 4 Through Week 48/96 - Study Eye

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Mean · micrometers

Average Change From Baseline in CSFTtot Over the Period Week 4 Through Week 48/96 - Study Eye
micrometers	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline over the period Week 4 to 48	-161.0 ± 138.65	-165.2 ± 135.36	-149.3 ± 128.16
Change from baseline over the period Week 4 to 96	-167.5 ± 143.12	-167.8 ± 141.23	-152.4 ± 135.75

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -16.0 · 95% CI -32.6 to 0.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -19.9 · 95% CI -36.5 to -3.3Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -18.9 · 95% CI -36.4 to -1.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -19.3 · 95% CI -36.9 to -1.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryChange From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye

CNV lesion size (the area of new blood vessels in the choroid layer of the retina) size was measured using fluorescein angiography (FA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.

Time frame:: Baseline, Weeks 12, 48, 96
Reported as:: Mean · millimeters squared

Change From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye
millimeters squared	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 12	-3.3 ± 4.15	-3.8 ± 3.89	-3.2 ± 3.45
Change from baseline at Week 48	-3.9 ± 4.59	-4.0 ± 3.89	-3.5 ± 4.03
Change from baseline at Week 96	-3.9 ± 4.62	-4.1 ± 4.07	-3.5 ± 4.17

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.3 · 95% CI -0.8 to 0.1Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.6 · 95% CI -1.0 to -0.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.7 · 95% CI -1.1 to -0.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.5 · 95% CI -0.9 to 0.0Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.8 · 95% CI -1.3 to -0.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.7 · 95% CI -1.1 to -0.3Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryChange From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye

Central subfield neurosensory retinal thickness was assessed using SD-OCT. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Time frame:: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Mean · micrometers

Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye
micrometers	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 4	-56.3 ± 86.09	-62.1 ± 88.73	-61.0 ± 85.59
Change from baseline at Week 8	-63.7 ± 87.09	-66.3 ± 93.11	-63.2 ± 88.65
Change from baseline at Week 12	-67.0 ± 88.75	-68.3 ± 94.14	-63.7 ± 88.73
Change from baseline at Week 16	-57.2 ± 91.00	-61.1 ± 92.12	-54.9 ± 91.55
Change from baseline at Week 20	-58.6 ± 90.20	-59.4 ± 91.78	-65.5 ± 89.46
Change from baseline at Week 24	-63.4 ± 91.06	-65.0 ± 97.16	-57.3 ± 91.89
Change from baseline at Week 28	-67.9 ± 92.89	-66.1 ± 98.08	-67.2 ± 89.40
Change from baseline at Week 32	-58.6 ± 93.16	-60.4 ± 97.42	-59.0 ± 90.77
Change from baseline at Week 36	-67.4 ± 94.43	-69.2 ± 100.29	-67.1 ± 92.55
Change from baseline at Week 40	-64.0 ± 93.94	-67.0 ± 98.18	-61.8 ± 90.60
Change from baseline at Week 44	-65.2 ± 91.89	-67.4 ± 99.33	-67.5 ± 92.08
Change from baseline at Week 48	-66.3 ± 95.57	-66.4 ± 98.85	-64.3 ± 92.86
Change from baseline at Week 52	-70.4 ± 95.07	-69.8 ± 100.94	-69.5 ± 94.15
Change from baseline at Week 56	-66.9 ± 95.57	-65.0 ± 100.26	-65.2 ± 93.33
Change from baseline at Week 60	-73.0 ± 97.26	-69.0 ± 102.69	-69.9 ± 95.32
Change from baseline at Week 64	-69.5 ± 97.07	-68.3 ± 101.20	-66.5 ± 94.25
Change from baseline at Week 68	-69.5 ± 97.06	-68.4 ± 101.24	-69.0 ± 94.73
Change from baseline at Week 72	-70.8 ± 96.61	-68.4 ± 99.73	-65.1 ± 94.75
Change from baseline at Week 76	-70.0 ± 101.51	-70.8 ± 102.45	-69.1 ± 95.26
Change from baseline at Week 80	-67.2 ± 102.52	-68.2 ± 100.77	-67.1 ± 92.06
Change from baseline at Week 84	-72.7 ± 101.96	-71.3 ± 102.48	-69.6 ± 93.53
Change from baseline at Week 88	-71.5 ± 98.52	-69.3 ± 100.95	-66.9 ± 93.64
Change from baseline at Week 92	-71.6 ± 99.16	-71.2 ± 104.98	-70.3 ± 93.71
Change from baseline at Week 96	-71.8 ± 99.15	-70.4 ± 101.71	-64.9 ± 94.21

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 7.1 · 95% CI -3.3 to 17.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.3 · 95% CI -10.2 to 10.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.1 · 95% CI -8.4 to 12.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -1.6 · 95% CI -12.5 to 9.2Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.6 · 95% CI -11.2 to 10.0Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -3.0 · 95% CI -13.9 to 7.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.2 · 95% CI -11.1 to 11.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -4.8 · 95% CI -16.1 to 6.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 9.3 · 95% CI -1.6 to 20.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 7.6 · 95% CI -3.4 to 18.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -3.6 · 95% CI -14.7 to 7.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -6.3 · 95% CI -17.9 to 5.3Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.1 · 95% CI -8.8 to 12.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.6 · 95% CI -8.7 to 13.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.9 · 95% CI -8.4 to 14.1Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -11.7 to 11.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.4 · 95% CI -8.8 to 13.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.6 · 95% CI -12.2 to 10.9Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.5 · 95% CI -10.7 to 11.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -3.6 · 95% CI -15.0 to 7.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 4.9 · 95% CI -6.1 to 15.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 1.5 · 95% CI -10.0 to 13.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.8 · 95% CI -10.5 to 12.1Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.6 · 95% CI -12.2 to 11.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 1.9 · 95% CI -9.5 to 13.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 1.2 · 95% CI -10.6 to 13.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.9 · 95% CI -10.6 to 12.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 1.6 · 95% CI -10.4 to 13.5Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.4 · 95% CI -11.9 to 11.2Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.4 · 95% CI -9.7 to 14.6Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -11.7 to 11.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -12.2 to 11.7Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.3 · 95% CI -9.3 to 13.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.1 · 95% CI -9.8 to 14.0Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -2.9 · 95% CI -14.5 to 8.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -1.8 · 95% CI -13.7 to 10.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 1.8 · 95% CI -10.0 to 13.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -12.2 to 11.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 2.8 · 95% CI -9.1 to 14.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.5 · 95% CI -11.3 to 12.3Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.2 · 95% CI -11.9 to 11.5Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.1 · 95% CI -12.0 to 11.7Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -1.7 · 95% CI -13.2 to 9.8Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -0.8 · 95% CI -12.6 to 11.0Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 1.7 · 95% CI -9.8 to 13.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: 0.9 · 95% CI -11.1 to 12.8Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -4.0 · 95% CI -15.6 to 7.6Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANOVA · Least squares mean difference: -3.9 · 95% CI -15.8 to 8.0Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryPercentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye

Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Time frame:: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Week 4	33.2 (28.4 to 38.4)	28.9 (24.3 to 33.9)	42.8 (37.6 to 48.1)
Week 8	19.0 (15.1 to 23.4)	12.8 (9.5 to 16.7)	27.5 (23.0 to 32.4)
Week 12	14.8 (11.3 to 18.9)	9.2 (6.4 to 12.6)	23.1 (18.8 to 27.8)
Week 16	26.0 (21.5 to 30.8)	16.9 (13.2 to 21.2)	36.7 (31.7 to 41.9)
Week 20	26.3 (21.8 to 31.1)	24.4 (20.1 to 29.2)	22.2 (18.0 to 26.9)
Week 24	23.5 (19.2 to 28.2)	13.1 (9.8 to 17.0)	36.4 (31.4 to 41.6)
Week 28	18.4 (14.6 to 22.8)	16.4 (12.7 to 20.6)	21.4 (17.3 to 26.0)
Week 32	28.2 (23.6 to 33.2)	23.9 (19.6 to 28.6)	36.1 (31.1 to 41.3)
Week 36	14.2 (10.8 to 18.3)	11.9 (8.8 to 15.8)	22.2 (18.0 to 26.9)
Week 40	21.5 (17.4 to 26.1)	16.1 (12.5 to 20.3)	27.5 (23.0 to 32.4)
Week 44	20.1 (16.1 to 24.6)	16.4 (12.7 to 20.6)	19.4 (15.5 to 23.9)
Week 48	18.2 (14.3 to 22.5)	14.4 (11.0 to 18.5)	30.0 (25.3 to 35.0)
Week 52	15.9 (12.3 to 20.1)	10.0 (7.1 to 13.6)	18.6 (14.7 to 23.0)
Week 56	20.4 (16.3 to 24.9)	18.1 (14.2 to 22.4)	27.5 (23.0 to 32.4)
Week 60	14.2 (10.8 to 18.3)	10.3 (7.3 to 13.9)	18.9 (15.0 to 23.3)
Week 64	18.7 (14.8 to 23.1)	14.4 (11.0 to 18.5)	26.4 (21.9 to 31.3)
Week 68	18.4 (14.6 to 22.8)	14.4 (11.0 to 18.5)	15.8 (12.2 to 20.0)
Week 72	16.2 (12.5 to 20.4)	11.4 (8.3 to 15.1)	23.9 (19.6 to 28.6)
Week 76	15.9 (12.3 to 20.1)	11.7 (8.5 to 15.4)	17.5 (13.7 to 21.8)
Week 80	17.6 (13.8 to 21.9)	12.2 (9.0 to 16.1)	23.9 (19.6 to 28.6)
Week 84	12.0 (8.8 to 15.8)	12.2 (9.0 to 16.1)	17.2 (13.5 to 21.5)
Week 88	17.3 (13.5 to 21.6)	11.7 (8.5 to 15.4)	23.3 (19.1 to 28.1)
Week 92	15.9 (12.3 to 20.1)	10.0 (7.1 to 13.6)	15.0 (11.5 to 19.1)
Week 96	15.6 (12.0 to 19.8)	10.3 (7.3 to 13.9)	21.4 (17.3 to 26.0)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -9.4 · 95% CI -16.4 to -3.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -14.2 · 95% CI -21.3 to -7.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.4 · 95% CI -14.6 to -2.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -15.0 · 95% CI -20.9 to -9.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.1 · 95% CI -13.8 to -2.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -14.0 · 95% CI -18.9 to -8.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -10.4 · 95% CI -16.8 to -3.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -19.7 · 95% CI -25.8 to -13.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.1 · 95% CI -2.0 to 9.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -4.3 to 7.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.7 · 95% CI -19.1 to -6.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -23.4 · 95% CI -29.7 to -17.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.8 · 95% CI -8.7 to 3.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.1 · 95% CI -11.2 to 0.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.7 · 95% CI -14.3 to -1.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.4 · 95% CI -19.3 to -6.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.8 · 95% CI -13.2 to -2.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -10.3 · 95% CI -15.9 to -4.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.6 · 95% CI -11.5 to 0.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -11.4 · 95% CI -17.7 to -5.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -5.1 to 6.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.1 · 95% CI -8.7 to 2.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -11.6 · 95% CI -17.8 to -5.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -15.6 · 95% CI -21.2 to -9.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.6 · 95% CI -8.0 to 3.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.6 · 95% CI -13.7 to -3.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.9 · 95% CI -12.6 to -0.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -9.6 · 95% CI -16.0 to -3.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.5 · 95% CI -9.9 to 0.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.5 · 95% CI -13.9 to -3.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.4 · 95% CI -13.1 to -1.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.0 · 95% CI -17.8 to -6.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.7 · 95% CI -2.5 to 8.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.4 · 95% CI -6.7 to 3.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.5 · 95% CI -12.8 to -1.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.5 · 95% CI -18.2 to -7.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.4 · 95% CI -7.0 to 4.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.9 · 95% CI -11.4 to -0.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.1 · 95% CI -11.8 to -0.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -11.7 · 95% CI -17.0 to -6.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.1 · 95% CI -10.1 to 0.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.1 · 95% CI -10.0 to -0.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.7 · 95% CI -11.7 to 0.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -11.7 · 95% CI -17.3 to -6.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -4.0 to 6.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.0 · 95% CI -9.7 to -0.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.5 · 95% CI -11.4 to -0.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -11.1 · 95% CI -16.4 to -6.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye

Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Time frame:: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Week 4	20.4 (16.3 to 24.9)	23.9 (19.6 to 28.6)	22.2 (18.0 to 26.9)
Week 8	17.9 (14.0 to 22.2)	20.8 (16.8 to 25.4)	22.5 (18.3 to 27.2)
Week 12	14.2 (10.8 to 18.3)	17.2 (13.5 to 21.5)	16.9 (13.2 to 21.2)
Week 16	22.3 (18.1 to 27.0)	20.3 (16.2 to 24.8)	24.7 (20.4 to 29.5)
Week 20	25.7 (21.2 to 30.6)	25.0 (20.6 to 29.8)	15.0 (11.5 to 19.1)
Week 24	22.9 (18.7 to 27.6)	17.8 (14.0 to 22.1)	26.9 (22.4 to 31.8)
Week 28	21.8 (17.6 to 26.4)	18.1 (14.2 to 22.4)	18.9 (15.0 to 23.3)
Week 32	24.6 (20.2 to 29.4)	21.9 (17.8 to 26.6)	24.4 (20.1 to 29.2)
Week 36	17.9 (14.0 to 22.2)	16.4 (12.7 to 20.6)	18.6 (14.7 to 23.0)
Week 40	20.7 (16.6 to 25.2)	19.7 (15.7 to 24.2)	24.2 (19.8 to 28.9)
Week 44	21.5 (17.4 to 26.1)	18.6 (14.7 to 23.0)	16.7 (13.0 to 20.9)
Week 48	21.8 (17.6 to 26.4)	21.4 (17.3 to 26.0)	22.2 (18.0 to 26.9)
Week 52	18.4 (14.6 to 22.8)	16.9 (13.2 to 21.2)	15.0 (11.5 to 19.1)
Week 56	23.7 (19.4 to 28.5)	20.8 (16.8 to 25.4)	21.1 (17.0 to 25.7)
Week 60	15.1 (11.5 to 19.2)	15.8 (12.2 to 20.0)	16.4 (12.7 to 20.6)
Week 64	20.4 (16.3 to 24.9)	17.8 (14.0 to 22.1)	20.8 (16.8 to 25.4)
Week 68	19.8 (15.8 to 24.3)	16.4 (12.7 to 20.6)	14.2 (10.7 to 18.2)
Week 72	17.6 (13.8 to 21.9)	15.0 (11.5 to 19.1)	18.3 (14.5 to 22.7)
Week 76	17.3 (13.5 to 21.6)	15.6 (12.0 to 19.7)	14.2 (10.7 to 18.2)
Week 80	19.3 (15.3 to 23.7)	18.6 (14.7 to 23.0)	18.3 (14.5 to 22.7)
Week 84	16.8 (13.0 to 21.0)	14.2 (10.7 to 18.2)	14.4 (11.0 to 18.5)
Week 88	20.7 (16.6 to 25.2)	16.7 (13.0 to 20.9)	16.7 (13.0 to 20.9)
Week 92	17.6 (13.8 to 21.9)	14.4 (11.0 to 18.5)	13.6 (10.2 to 17.6)
Week 96	19.3 (15.3 to 23.7)	15.0 (11.5 to 19.1)	20.0 (16.0 to 24.5)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.0 · 95% CI -7.9 to 3.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -4.1 to 7.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.5 · 95% CI -10.0 to 1.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.5 · 95% CI -7.7 to 4.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.7 · 95% CI -7.6 to 2.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -5.4 to 5.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.5 · 95% CI -8.3 to 3.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.3 · 95% CI -10.0 to 1.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 10.6 · 95% CI 5.0 to 16.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 10.0 · 95% CI 4.7 to 15.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.0 · 95% CI -9.8 to 1.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -9.0 · 95% CI -14.9 to -3.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.9 · 95% CI -2.1 to 8.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -6.3 to 5.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.0 · 95% CI -5.8 to 6.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.5 · 95% CI -8.4 to 3.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.0 · 95% CI -6.4 to 4.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.3 · 95% CI -7.8 to 3.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.8 · 95% CI -9.6 to 1.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.6 · 95% CI -10.2 to 1.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.6 · 95% CI -1.0 to 9.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -3.3 to 7.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.6 · 95% CI -6.2 to 5.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -6.4 to 5.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.3 · 95% CI -2.2 to 8.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.9 · 95% CI -3.2 to 7.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.3 · 95% CI -3.5 to 8.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -5.8 to 5.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.5 · 95% CI -6.6 to 3.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.5 · 95% CI -5.8 to 5.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -6.4 to 5.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.0 · 95% CI -8.7 to 2.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 5.5 · 95% CI 0.3 to 10.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.2 · 95% CI -3.2 to 7.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.9 · 95% CI -6.1 to 4.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.4 · 95% CI -9.0 to 1.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.1 · 95% CI -1.9 to 8.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.3 · 95% CI -3.9 to 6.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.7 · 95% CI -4.7 to 6.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.2 · 95% CI -5.2 to 6.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -3.3 to 7.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.3 · 95% CI -5.7 to 4.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.9 · 95% CI -1.7 to 9.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.1 · 95% CI -5.3 to 5.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 3.8 · 95% CI -1.3 to 8.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.9 · 95% CI -4.3 to 6.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.9 · 95% CI -6.4 to 5.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.9 · 95% CI -10.8 to 0.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye

Sub-RPE fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of sub-RPE fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Time frame:: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Week 4	25.4 (21.0 to 30.3)	24.2 (19.8 to 28.9)	29.2 (24.5 to 34.2)
Week 8	16.5 (12.8 to 20.7)	17.5 (13.7 to 21.8)	21.4 (17.3 to 26.0)
Week 12	13.7 (10.3 to 17.7)	14.2 (10.7 to 18.2)	21.1 (17.0 to 25.7)
Week 16	19.3 (15.3 to 23.7)	18.9 (15.0 to 23.3)	26.9 (22.4 to 31.8)
Week 20	19.8 (15.8 to 24.3)	20.6 (16.5 to 25.1)	17.8 (14.0 to 22.1)
Week 24	17.3 (13.5 to 21.6)	16.1 (12.5 to 20.3)	22.8 (18.5 to 27.5)
Week 28	18.7 (14.8 to 23.1)	15.6 (12.0 to 19.7)	18.3 (14.5 to 22.7)
Week 32	19.8 (15.8 to 24.3)	19.7 (15.7 to 24.2)	21.4 (17.3 to 26.0)
Week 36	12.8 (9.6 to 16.8)	13.1 (9.8 to 17.0)	18.1 (14.2 to 22.4)
Week 40	17.0 (13.3 to 21.3)	16.7 (13.0 to 20.9)	22.5 (18.3 to 27.2)
Week 44	16.2 (12.5 to 20.4)	13.9 (10.5 to 17.9)	18.1 (14.2 to 22.4)
Week 48	16.5 (12.8 to 20.7)	13.6 (10.2 to 17.6)	21.4 (17.3 to 26.0)
Week 52	12.8 (9.6 to 16.8)	12.8 (9.5 to 16.7)	13.9 (10.5 to 17.9)
Week 56	15.6 (12.0 to 19.8)	15.0 (11.5 to 19.1)	20.6 (16.5 to 25.1)
Week 60	12.6 (9.3 to 16.5)	13.1 (9.8 to 17.0)	15.3 (11.7 to 19.4)
Week 64	14.2 (10.8 to 18.3)	13.3 (10.0 to 17.3)	20.0 (16.0 to 24.5)
Week 68	13.7 (10.3 to 17.7)	14.2 (10.7 to 18.2)	15.3 (11.7 to 19.4)
Week 72	11.7 (8.6 to 15.5)	10.8 (7.8 to 14.5)	17.8 (14.0 to 22.1)
Week 76	12.0 (8.8 to 15.8)	12.5 (9.3 to 16.4)	13.3 (10.0 to 17.3)
Week 80	11.7 (8.6 to 15.5)	12.8 (9.5 to 16.7)	15.8 (12.2 to 20.0)
Week 84	11.5 (8.3 to 15.2)	11.7 (8.5 to 15.4)	16.7 (13.0 to 20.9)
Week 88	14.5 (11.0 to 18.6)	11.4 (8.3 to 15.1)	17.2 (13.5 to 21.5)
Week 92	12.6 (9.3 to 16.5)	10.3 (7.3 to 13.9)	13.1 (9.8 to 17.0)
Week 96	13.7 (10.3 to 17.7)	11.1 (8.1 to 14.8)	14.4 (11.0 to 18.5)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.3 · 95% CI -7.7 to 3.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.7 · 95% CI -11.4 to 0.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.8 · 95% CI -9.3 to 1.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.4 · 95% CI -9.8 to 1.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.5 · 95% CI -11.5 to -1.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.6 · 95% CI -12.8 to -2.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.5 · 95% CI -11.8 to -1.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.6 · 95% CI -14.4 to -2.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.7 · 95% CI -2.8 to 8.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.1 · 95% CI -3.4 to 7.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.6 · 95% CI -9.7 to 0.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.1 · 95% CI -12.3 to -1.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.1 · 95% CI -4.2 to 6.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.2 · 95% CI -8.4 to 1.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.7 · 95% CI -6.2 to 5.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.4 · 95% CI -7.5 to 3.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.5 · 95% CI -9.5 to 0.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.4 · 95% CI -10.6 to -0.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.6 · 95% CI -10.2 to 1.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.3 · 95% CI -12.2 to -0.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.2 · 95% CI -6.6 to 4.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.7 · 95% CI -10.0 to 0.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.0 · 95% CI -9.4 to 1.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.1 · 95% CI -13.6 to -2.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.4 · 95% CI -5.1 to 4.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.6 · 95% CI -6.2 to 2.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.2 · 95% CI -9.4 to 1.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.2 · 95% CI -11.5 to -0.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.3 · 95% CI -7.3 to 3.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.7 · 95% CI -7.9 to 2.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.2 · 95% CI -10.5 to 0.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.1 · 95% CI -12.5 to -1.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.0 · 95% CI -6.0 to 4.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.3 · 95% CI -6.3 to 3.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.4 · 95% CI -10.1 to -0.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.3 · 95% CI -12.2 to -2.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.8 · 95% CI -5.2 to 4.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -1.0 · 95% CI -5.8 to 3.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.4 · 95% CI -8.4 to 1.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.3 · 95% CI -8.5 to 1.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.7 · 95% CI -9.8 to 0.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.4 · 95% CI -10.4 to -0.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.2 · 95% CI -7.4 to 3.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.0 · 95% CI -11.0 to -1.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -4.9 to 5.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.0 · 95% CI -7.6 to 1.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -5.3 to 5.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.8 · 95% CI -8.5 to 0.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryPercentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid at Each Post-baseline Visit - Study Eye

Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Time frame:: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid at Each Post-baseline Visit - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Week 4	47.8 (42.5 to 53.1)	47.2 (42.0 to 52.5)	54.7 (49.4 to 59.9)
Week 8	32.7 (27.8 to 37.8)	30.3 (25.6 to 35.3)	42.5 (37.3 to 47.8)
Week 12	26.0 (21.5 to 30.8)	24.2 (19.8 to 28.9)	34.4 (29.5 to 39.6)
Week 16	41.6 (36.5 to 46.9)	33.9 (29.0 to 39.0)	52.2 (46.9 to 57.5)
Week 20	45.3 (40.0 to 50.6)	44.4 (39.2 to 49.7)	33.3 (28.5 to 38.5)
Week 24	39.9 (34.8 to 45.2)	27.5 (23.0 to 32.4)	50.8 (45.5 to 56.1)
Week 28	36.9 (31.9 to 42.1)	31.4 (26.6 to 36.5)	35.3 (30.3 to 40.5)
Week 32	45.5 (40.3 to 50.8)	40.0 (34.9 to 45.3)	50.3 (45.0 to 55.6)
Week 36	28.8 (24.1 to 33.8)	25.6 (21.1 to 30.4)	34.7 (29.8 to 39.9)
Week 40	37.2 (32.1 to 42.4)	32.5 (27.7 to 37.6)	45.6 (40.3 to 50.9)
Week 44	38.3 (33.2 to 43.5)	32.2 (27.4 to 37.3)	32.2 (27.4 to 37.3)
Week 48	34.1 (29.2 to 39.2)	31.1 (26.4 to 36.2)	44.7 (39.5 to 50.0)
Week 52	30.7 (26.0 to 35.8)	24.7 (20.4 to 29.5)	29.7 (25.0 to 34.7)
Week 56	38.8 (33.7 to 44.1)	35.0 (30.1 to 40.2)	41.9 (36.8 to 47.2)
Week 60	27.1 (22.6 to 32.0)	23.6 (19.3 to 28.3)	30.8 (26.1 to 35.9)
Week 64	33.5 (28.6 to 38.7)	28.9 (24.3 to 33.9)	41.1 (36.0 to 46.4)
Week 68	34.1 (29.2 to 39.2)	29.2 (24.5 to 34.2)	26.9 (22.4 to 31.8)
Week 72	27.9 (23.3 to 32.9)	24.4 (20.1 to 29.2)	36.9 (31.9 to 42.2)
Week 76	28.8 (24.1 to 33.8)	25.3 (20.9 to 30.1)	28.6 (24.0 to 33.6)
Week 80	32.1 (27.3 to 37.2)	28.6 (24.0 to 33.6)	36.7 (31.7 to 41.9)
Week 84	26.3 (21.8 to 31.1)	23.9 (19.6 to 28.6)	28.3 (23.7 to 33.3)
Week 88	32.7 (27.8 to 37.8)	26.1 (21.6 to 31.0)	36.7 (31.7 to 41.9)
Week 92	29.9 (25.2 to 34.9)	22.8 (18.5 to 27.5)	25.8 (21.4 to 30.7)
Week 96	30.4 (25.7 to 35.5)	23.9 (19.6 to 28.6)	36.9 (31.9 to 42.2)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.7 · 95% CI -14.1 to 0.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.4 · 95% CI -15.3 to -0.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -9.3 · 95% CI -16.6 to -2.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.1 · 95% CI -19.7 to -5.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.2 · 95% CI -14.8 to -1.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -10.2 · 95% CI -17.4 to -3.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · p = 0.0030 (1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg) · Difference in proportions: -10.2 · 95% CI -17.3 to -2.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · p = <0.0001 (1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg) · Difference in proportions: -18.2 · 95% CI -25.3 to -10.9Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 12.0 · 95% CI 5.2 to 19.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 11.1 · 95% CI 3.8 to 18.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -10.6 · 95% CI -17.7 to -3.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -23.2 · 95% CI -30.5 to -16.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.7 · 95% CI -4.8 to 9.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.9 · 95% CI -11.8 to 2.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.5 · 95% CI -12.0 to 3.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -10.3 · 95% CI -18.0 to -3.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -5.9 · 95% CI -12.5 to 0.8Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -9.2 · 95% CI -16.2 to -2.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.2 · 95% CI -15.7 to -0.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -13.0 · 95% CI -20.5 to -5.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 6.0 · 95% CI -0.8 to 13.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -0.1 · 95% CI -7.5 to 6.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · p = 0.0020 (1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg) · Difference in proportions: -10.5 · 95% CI -17.4 to -3.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · p = 0.0001 (1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg) · Difference in proportions: -13.5 · 95% CI -20.7 to -6.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 1.0 · 95% CI -5.4 to 8.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.9 · 95% CI -11.8 to 1.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.2 · 95% CI -10.3 to 3.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.9 · 95% CI -14.1 to 0.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.8 · 95% CI -10.1 to 3.3Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.1 · 95% CI -14.0 to -0.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -7.6 · 95% CI -14.7 to -0.1Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.1 · 95% CI -19.5 to -5.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 7.2 · 95% CI 0.3 to 13.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 2.2 · 95% CI -4.9 to 8.4Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.9 · 95% CI -15.7 to -1.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.5 · 95% CI -19.8 to -5.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 0.3 · 95% CI -5.9 to 7.2Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.4 · 95% CI -9.8 to 2.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.4 · 95% CI -11.2 to 2.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -8.1 · 95% CI -15.3 to -1.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -2.1 · 95% CI -8.9 to 4.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -4.5 · 95% CI -11.2 to 1.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.8 · 95% CI -10.8 to 3.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -10.3 · 95% CI -17.3 to -3.5Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: 4.1 · 95% CI -2.3 to 11.0Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -3.0 · 95% CI -9.8 to 2.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -6.4 · 95% CI -13.2 to 0.7Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 3mg - Aflibercept 2mg) was estimated using a bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · Difference in proportions: -12.9 · 95% CI -19.7 to -6.6Statistical model used logistic regression adjusting for baseline fluid status, age categories, and treatment as fixed effect factors. 95% CI for difference in proportions (Brolucizumab 6mg - Aflibercept 2mg) was estimated using a bootstrap method.

SecondaryNumber of Subjects With Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) Present Between Week 36 to Week 48, Reported by Number of Visits

Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis. For each subject, the number of visits with SRF and/or IRF fluid is analyzed.

Time frame:: Weeks 36, 40, 44, 48
Reported as:: Number · subjects

Number of Subjects With Subretinal Fluid (SRF) and/or Intraretinal Fluid (IRF) Present Between Week 36 to Week 48, Reported by Number of Visits
subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
0 Visits	154	171	153
1 Visit	67	73	48
2 Visits	47	39	39
3 Visits	26	22	40
4 Visits	64	55	60

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Cochran-Mantel-Haenszel · p = 0.0574 (1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg)CMH-test row mean score (scores=table) stratified by age categories (\<75, ≥75 years) and baseline fluid status)
Brolucizumab 6 mg vs Aflibercept 2 mg · Cochran-Mantel-Haenszel · p = 0.0012 (1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg)CMH-test row mean score (scores=table) stratified by age categories (\<75, ≥75 years) and baseline fluid status)

SecondaryPercentage of Subjects With Disease Activity Present (q8 Treatment Need = "Yes") at Week 16 - Study Eye

A disease activity assessment (DAA) was performed to identify q8 treatment need. 95% CI for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Time frame:: Week 16
Reported as:: Number · percentage of subjects

Percentage of Subjects With Disease Activity Present (q8 Treatment Need = "Yes") at Week 16 - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Percentage of Subjects With Disease Activity Present (q8 Treatment Need = "Yes") at Week 16 - Study Eye	28.0 (23.4 to 33.0)	24.0 (19.6 to 28.8)	34.6 (29.6 to 39.9)

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · Regression, Logistic · p = 0.0331 (1-sided testing for superiority of brolucizumab 3 mg versus aflibercept 2 mg) · Difference in proportions: -6.5 · 95% CI -13.2 to 0.3Statistical model used logistic regression adjusting for age categories (\<75, \>=75 years) and treatment as fixed effect factors. 95% CI for the treatment difference estimated using bootstrap method.
Brolucizumab 6 mg vs Aflibercept 2 mg · Regression, Logistic · p = 0.0013 (1-sided testing for superiority of brolucizumab 6 mg versus aflibercept 2 mg) · Difference in proportions: -10.5 · 95% CI -17.1 to -3.5Statistical model used logistic regression adjusting for age categories (\<75, \>=75 years) and treatment as fixed effect factors. 95% CI for the treatment difference estimated using bootstrap method.

SecondaryChange From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96

The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) is a validated questionnaire that collects 25 vision-targeted responses from age-related macular degeneration (AMD) subjects. The 25 questions pertain to global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision (2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (1), and ocular pain (2). Each response is converted to a 0 to 100 sub-scale, with the lowest and highest possible scores set at 0 and 100 points, respectively. The overall composite score (0 to 100) is obtained by averaging the 25 sub-scale scores. A high score represents better functioning.

Time frame:: Baseline, Weeks 24, 48, 72, 96
Reported as:: Median · score on a scale

Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96
score on a scale	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Change from baseline at Week 24	4.4 ± 10.49	4.0 ± 12.20	3.5 ± 9.97
Change from baseline at Week 48	4.3 ± 11.44	4.1 ± 12.58	4.5 ± 10.64
Change from baseline at Week 72	4.4 ± 12.19	3.9 ± 12.53	4.0 ± 12.05
Change from baseline at Week 96	3.8 ± 13.53	3.8 ± 13.50	2.8 ± 13.28

Statistical analysis

Brolucizumab 3 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: 0.90 · 95% CI -0.5 to 2.3Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: 0.63 · 95% CI -0.9 to 2.1Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: -0.20 · 95% CI -1.8 to 1.4Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: -0.26 · 95% CI -1.9 to 1.4Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: 0.18 · 95% CI -1.6 to 1.9Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: -0.12 · 95% CI -1.9 to 1.7Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)
Brolucizumab 3 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: 0.75 · 95% CI -1.2 to 2.7Least squares mean difference (Brolucizumab 3mg - Aflibercept 2mg)
Brolucizumab 6 mg vs Aflibercept 2 mg · ANCOVA · Least squares mean difference: 1.05 · 95% CI -0.9 to 3.0Least squares mean difference (Brolucizumab 6mg - Aflibercept 2mg)

SecondaryPercentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) Status at Week 48 (Brolucizumab Only)

Serum samples were collected and assessed for anti-drug antibody status. Subjects were categorized as ADA negative when one of the following was met: ADA negative at all time points (predose and postdose); ADA negative at predose and no titer values above 10 at all other time points; or ADA titer of 10 at predose but negative at all other time points. ADA induced was defined as ADA negative at predose with postdose titer value greater than or equal to a titer of 30 at any timepoint. ADA boosted was defined as ADA positive at predose with postdose titer values that increased by at least two dilutions (9-fold) from their respective predose value at any time point. Hypothesis testing not pre-specified.

Time frame:: Week 48
Reported as:: Number · percentage of subjects

Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) Status at Week 48 (Brolucizumab Only)
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) Status at Week 48 (Brolucizumab Only)	25.6	20.4	65.8

SecondaryPercentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye

Intraretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

Time frame:: Baseline, Weeks 12, 48, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Week 12	0.0	0.3	0.9
Week 48	0.0	0.0	0.0
Week 96	0.3	0.0	0.0

SecondaryPercentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye

Subretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal hemorrhage is an indicator of underlying disease. 95% CI for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

Time frame:: Baseline, Weeks 12, 48, 96
Reported as:: Number · percentage of subjects

Percentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye
percentage of subjects	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg
Week 12	1.6	2.4	0.7
Week 48	1.8	0.4	2.6
Week 96	0.7	0.8	1.6

Adverse events

Collected over First treatment through study completion, an average of 96 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
Group	Deaths	Serious	Other
Brolucizumab 3mg	9/358 (2.5%)	94/358 (26.3%)	239/358 (66.8%)
Brolucizumab 6mg	8/360 (2.2%)	95/360 (26.4%)	228/360 (63.3%)
Aflibercept 2mg	12/360 (3.3%)	114/360 (31.7%)	228/360 (63.3%)

Most frequent serious events

Showing 10 of 251

Most frequent serious events
Event	Brolucizumab 3mg	Brolucizumab 6mg	Aflibercept 2mg
PneumoniaInfections and infestations	7/358	10/360	9/360
Coronary artery diseaseCardiac disorders	6/358	1/360	3/360
Cardiac failure congestiveCardiac disorders	4/358	6/360	4/360
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders	1/358	6/360	4/360
Atrial fibrillationCardiac disorders	4/358	4/360	2/360
CholelithiasisHepatobiliary disorders	4/358	1/360	2/360
Urinary tract infectionInfections and infestations	4/358	2/360	2/360
HyponatraemiaMetabolism and nutrition disorders	4/358	2/360	1/360
SepsisInfections and infestations	3/358	4/360	1/360
Femur fractureInjury, poisoning and procedural complications	0/358	2/360	4/360

Most frequent other events

Showing 10 of 20

Most frequent other events
Event	Brolucizumab 3mg	Brolucizumab 6mg	Aflibercept 2mg
NasopharyngitisInfections and infestations	44/358	38/360	44/360
Urinary tract infectionInfections and infestations	39/358	26/360	40/360
Conjunctival haemorrhage - Study eyeEye disorders	39/358	29/360	32/360
Visual acuity reduced - Study eyeEye disorders	34/358	21/360	27/360
Neovascular age-related macular degeneration - Fellow eyeEye disorders	33/358	32/360	31/360
HypertensionVascular disorders	33/358	25/360	23/360
Eye pain - Study eyeEye disorders	28/358	18/360	21/360
Vitreous floaters - Study eyeEye disorders	26/358	22/360	16/360
Back painMusculoskeletal and connective tissue disorders	26/358	13/360	17/360
Dry eye - Study eyeEye disorders	20/358	19/360	26/360

Baseline characteristics

This analysis population includes all randomized subjects who received at least 1 IVT injection of study treatment (Full Analysis Set).

Age, Continuous
Age, Continuous(years)	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg	Total
Mean	76.7 ± 8.28	76.7 ± 8.95	76.2 ± 8.80	76.5 ± 8.68

Age, Customized
Age, Customized(Participants)	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg	Total
Less than 50 years	0	0	0	0
50-64 years	31	35	37	103
65-74 years	103	103	112	318
75-84 years	162	155	148	465
85 years and greater	62	67	63	192

Sex: Female, Male
Sex: Female, Male(Participants)	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg	Total
Female	210	205	194	609
Male	148	155	166	469

Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg	Total
Hispanic or Latino	32	29	40	101
Not Hispanic or Latino	323	329	319	971
Unknown or Not Reported	3	2	1	6

Race (NIH/OMB)
Race (NIH/OMB)(Participants)	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg	Total
American Indian or Alaska Native	1	1	1	3
Asian	44	61	53	158
Native Hawaiian or Other Pacific Islander	0	0	0	0
Black or African American	1	1	1	3
White	302	285	287	874
More than one race	1	3	1	5
Unknown or Not Reported	9	9	17	35

Best Corrected Visual Acuity (BCVA) (letters read)
Best Corrected Visual Acuity (BCVA) (letters read)(letters)	Brolucizumab 3 mg	Brolucizumab 6 mg	Aflibercept 2 mg	Total
Mean	61.0 ± 13.57	60.8 ± 13.66	60.0 ± 13.92	60.6 ± 13.71

Study locations

1 site

Contact Alcon Call Center for Trial Locations
Fort Worth, Texas 76134, United States

References and documents

Publications

Singh RP, Jhaveri C, Wykoff CC, Gale RP, Staurenghi G, Iida T, Koh A, B G, Gedif K, Singer M. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid. Ophthalmol Retina. 2022 May;6(5):377-386. doi: 10.1016/j.oret.2021.12.014. Epub 2021 Dec 27. PubMed 34968756 ↗
Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK, Pruente C, Murray TG, Heier JS. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15. PubMed 33207259 ↗
Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12. PubMed 30986442 ↗

Study documents

Study protocol · Aug 7, 2017
Statistical analysis plan · Jun 12, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Registry details

Key details

Study ID: NCT02307682
Lead sponsor: Alcon Research
Responsible party: Sponsor
First posted: Dec 4, 2014
Start date: Dec 8, 2014
Primary completion: Apr 22, 2017
Completion: Mar 28, 2018
Results posted: Oct 31, 2019
Last update: Jan 16, 2025

Study contacts

Group Trial Lead

study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Macular Degeneration→

Other studies from this sponsor

Alcon Research

Start the discussion